tirabrutinib

a Bruton tyrosine kinase with antineoplastic activity; in phase I clinical trials (2016); structure in first source

Also Known As:

6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one, 6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-; GS-4059; ONO-4059

Networked: 48 relevant articles (8 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - tirabrutinib: 48
  - Pyrimidines: 510
    - tirabrutinib: 48

Experts

1.	Jürgensmeier, Juliane M: 6 articles (06/2022 - 10/2018)
2.	Bhargava, Pankaj: 4 articles (06/2022 - 01/2020)
3.	Fukuhara, Noriko: 4 articles (06/2022 - 05/2019)
4.	Dyer, Martin J S: 4 articles (01/2021 - 04/2018)
5.	Sekiguchi, Naohiro: 3 articles (12/2022 - 09/2020)
6.	Li, Biao: 3 articles (06/2022 - 01/2021)
7.	Munakata, Wataru: 3 articles (06/2022 - 05/2019)
8.	Rajakumaraswamy, Nishanthan: 3 articles (06/2022 - 01/2021)
9.	Terui, Yasuhito: 3 articles (06/2022 - 09/2020)
10.	Humeniuk, Rita: 3 articles (01/2022 - 01/2020)

Related Diseases

1.	Neoplasms (Cancer) 04/01/2021 - "Tirabrutinib irreversibly and covalently binds to BTK in B cells and has demonstrated effective in vitro cytotoxicity in many types of B-cell malignancies and in vivo antitumor activity in mouse models. " 04/01/2023 - "These findings demonstrate the long-term safety and efficacy of tirabrutinib in Japanese patients with B-cell malignancies.Clinical" 04/01/2023 - "We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. " 04/01/2023 - "Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies." 05/01/2019 - "Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan."
2.	Waldenstrom Macroglobulinemia (Macroglobulinemia) 06/01/2022 - "Taken together, tirabrutinib has durable efficacy with an acceptable safety profile for treatment-naïve and refractory/relapsed Waldenström's macroglobulinemia." 06/01/2022 - "The phase II study of tirabrutinib monotherapy at a daily dose of 480 mg under fasting conditions for treatment-naïve and relapsed/refractory Waldenström's macroglobulinemia (ONO-4059-05 study) demonstrated a promising efficacy and tolerable safety profile. " 09/01/2020 - "Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström's macroglobulinemia (WM). " 09/01/2020 - "A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia." 12/01/2022 - "The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia."
3.	Lymphoma (Lymphomas) 01/01/2023 - "Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib." 11/01/2023 - "This case report describes the use of tirabrutinib to treat 2 individuals with vitreoretinal lymphoma." 02/01/2023 - "Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib." 01/01/2023 - "[An elderly patient with lymphoplasmacytic lymphoma successfully treated with low-dose tirabrutinib]." 08/01/2022 - "Experience With Tirabrutinib in the Treatment of Primary Central Nervous System Lymphoma that Is Difficult to Treat With Standard Treatment."
4.	Pemphigus (Pemphigus Vulgaris) 09/01/2021 - "Thus, oral tirabrutinib may be a new treatment option for patients with refractory pemphigus." 09/01/2021 - "We investigated the efficacy and safety of tirabrutinib in patients with refractory pemphigus. " 09/01/2021 - "Tirabrutinib is a highly selective oral Bruton's tyrosine kinase inhibitor that may be clinically effective in treating pemphigus by suppressing B-cell signaling. " 09/01/2021 - "Treatment with tirabrutinib enabled remission and reduced oral corticosteroid exposure over time and did not result in any major safety concerns in patients with refractory pemphigus. " 09/01/2021 - "A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus."
5.	Pancytopenia 01/01/2022 - "Tirabrutinib is well tolerated and effective for relapsed primary DLBCL of the CNS with comorbidities, including cirrhosis and pancytopenia. " 01/01/2022 - "Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia." 01/01/2022 - "We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT). "

Related Drugs and Biologics

1.	Agammaglobulinaemia Tyrosine Kinase
2.	ibrutinib
3.	zanubrutinib
4.	acalabrutinib
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	orelabrutinib
7.	idelalisib
8.	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amine
9.	fenebrutinib
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Therapeutics
3.	Hematopoietic Stem Cell Transplantation
4.	Oral Administration